Quick Answer
Petros Pharmaceuticals, Inc. reported Net Income of -$14.32 million for fiscal year 2024.
Petros Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$14.32M | -75.4% |
| 2023 | -$8.16M | +59.3% |
| 2022 | -$20.04M | -123.0% |
| 2021 | -$8.99M | +56.3% |
| 2020 | -$20.59M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$922.7K | +58.4% | -117.0% |
| June 30, 2025 | $5.43M | +920.6% | +340.4% |
| March 31, 2025 | -$2.26M | -4.5% | -1.8% |
| September 30, 2024 | -$2.22M | +51.2% | -235.4% |
| June 30, 2024 | -$662.0K | +74.0% | +69.4% |
| March 31, 2024 | -$2.16M | -56.1% | +52.5% |
| September 30, 2023 | -$4.55M | +67.1% | -78.6% |
| June 30, 2023 | -$2.55M | -40.6% | -83.9% |
- Petros Pharmaceuticals, Inc. showed a decrease of -75.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2024 period, Petros Pharmaceuticals, Inc.’s net income has grown by 30.4% (from -$20.59 million to -$14.32 million).
- The most recent figure is from Petros Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: